Ovarian Cancer | Specialty

Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer

September 18th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Precision Medicine Rapidly Being Incorporated Into Ovarian Cancer Care

September 18th 2017

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.

Combined Niraparib and Bevacizumab Shows Promising Activity in Recurrent Ovarian Cancer

September 12th 2017

The combination of bevacizumab plus niraparib demonstrated clinical activity in women with relapsed, platinum-sensitive epithelial ovarian cancer and had a manageable toxicity profile.

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer

September 10th 2017

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, and medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit, discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

September 9th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

Dr. Barber on SCORPION Trial in Ovarian Cancer

September 6th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses the importance of the SCORPION trial in ovarian cancer.

BRCA1/2 Mutation Genetic Status Linked With Platinum Resistance in Breast and Ovarian Cancers

August 31st 2017

Katherine Nathanson, MD, discusses how the genetics of BRCA1/2-associated tumors impacts tumor development in breast and ovarian cancer and response to treatment.

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

August 29th 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

August 17th 2017

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

FDA Approves Olaparib Tablets for Ovarian Cancer

August 17th 2017

The FDA has approved olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

PARP Inhibitors Are Changing Diagnostic and Therapeutic Landscape in Ovarian Cancer

August 16th 2017

PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

August 16th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

Expert Discusses Promise of Mirvetuximab Soravtansine in Ovarian Cancer

August 14th 2017

Kathleen Moore, MD, discusses the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.

Expert Weighs in on PARP Inhibitor Advances in Ovarian Cancer

August 8th 2017

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Comprehensive Genomic Profiling May Identify Select Subsets in Ovarian Cancer

August 7th 2017

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.

Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

August 2nd 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

Maintenance Olaparib Data Published as FDA Weighs Approval

August 1st 2017

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

AstraZeneca: Pioneers in Ovarian Cancer

July 18th 2017

Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.

Emerging Novel Agents for Ovarian Cancer

July 14th 2017